RESULTS: Baseline data were obtained from 370 patients from 86 urologists and 22 practices. 210 patients completed the 30-day post RARP survey. 85% (n[179) of patients were prescribed opioids post RARP. Median MME prescribed was 75 per patient (about 10 tablets of oxycodone 5 mg). Median MME consumed was 28.5 per patient (about 4 tablets of oxycodone 5 mg) (Figure 1 ). 6% (n[12) of patients requested a refill. 2% (n[5) reported using opioids at 30 days. Median MME prescribed for those who requested refills or were using opioids at 30 days was 73 and 128, respectively. There was no difference in pain at 30 days post RARP versus at baseline.
INTRODUCTION AND OBJECTIVES:
Increasing deaths attributed to opioid drugs have become a major public health problem in the United States. Undergoing major surgery may trigger opioid addiction. We sought to investigate differences in the number of days of prescribed opioids after differing surgical approach (open vs. robotic) for major urologic procedures.
METHODS: We used the IBM Watson Health MarketscanÒ Commerical Claims and Encounters Database to identify opioid-ïve individuals aged 18-64 who underwent either radical prostatectomy, radical or partial nephrectomy or cystectomy between 2012 -2017. Propensity weighted multivariable regression analyses were used to determine the independent effect of surgical approach on the "days of opioids supplied" defined as opiod prescriptions within 90 days of surgery. Seven orally administered opioid analgesic agents were included in the analysis. We controlled for risk factors for chronic opioid abuse including history of depression, alcohol abuse, drug abuse, use of benzodiazepines, antidepressants, and antipsychotics within the year prior to surgery.
RESULTS data is available to appropriately tailor postdischarge opioid prescriptions after urologic surgery. The Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery (ORIOLES) initiative established an evidence-based reference value for opioid prescribing after radical prostatectomy and implemented a prospective intervention to reduce prescribing and use. The objective of the present study was to report on changes in opioid prescribing and use after intervention in the ORIOLES initiate.
METHODS: A prospective, non-randomized, pre-post cohort study of patients undergoing radical prostatectomy for prostate cancer (2017-2018) as part of ORIOLES was conducted. The primary outcome was total oral morphine equivalents (OMEQ) used after surgery with a reference value set to meet the needs of >80% of patients based on the pre-intervention cohort. Surgical approach and predictors of use were assessed via multivariable linear regression and mixed effects models. The post-intervention cohort all received an informational discharge sheet on opioid medications, nursing education, and standardized prescribing based on the reference value.
RESULTS: A total of 205 patients were included in the preintervention cohort and 87 patients in the post-intervention cohort. Prior to intervention, a median of 225mg OMEQ was prescribed, 22.5mg used, an overall 77% of medication unused, and 9.3% appropriate disposal of leftover medication. About 84% of patients required 112.5mg OMEQ with greater prescribing independently associated with greater opioid use in adjusted models. The postintervention cohort demonstrated a statistically significant reduction in OMEQ prescribed (-45.5%; mean 226.5mg to 123.4mg). OMEQ used was decreased (-21.5%; mean 52.5mg to 41.2mg) with a slight increase in disposal (þ7.6%; 9.3% to 16.9%) though these were not statistically significant with the current sample size. Only 6 (6.9%) patients required additional opioid medication in the post-intervention cohort.
CONCLUSIONS: Opioid pain medications are overprescribed relative to actual use by patients after radical prostatectomy with more opioids used when a greater quantity is prescribed. An appropriate baseline reference value for prescriptions after radical prostatectomy is 112.5mg OMEQ, which equates to 15 tablets of oxycodone 5 mg, with a simple prospective, evidence-based intervention associated with improved prescribing, use, and disposal.
